- Home
- SWIN vs MYGN Comparison
SWIN vs MYGN Comparison
Compare SWIN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIN
- MYGN
- Stock Information
- Founded
- SWIN 2017
- MYGN 1991
- Country
- SWIN Hong Kong
- MYGN United States
- Employees
- SWIN N/A
- MYGN N/A
- Industry
- SWIN
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SWIN
- MYGN Health Care
- Exchange
- SWIN Nasdaq
- MYGN Nasdaq
- Market Cap
- SWIN 541.0M
- MYGN 642.0M
- IPO Year
- SWIN 2023
- MYGN 1995
- Fundamental
- Price
- SWIN $2.63
- MYGN $7.68
- Analyst Decision
- SWIN
- MYGN Hold
- Analyst Count
- SWIN 0
- MYGN 13
- Target Price
- SWIN N/A
- MYGN $13.50
- AVG Volume (30 Days)
- SWIN 1.7M
- MYGN 1.4M
- Earning Date
- SWIN 06-30-2025
- MYGN 11-06-2025
- Dividend Yield
- SWIN N/A
- MYGN N/A
- EPS Growth
- SWIN N/A
- MYGN N/A
- EPS
- SWIN N/A
- MYGN N/A
- Revenue
- SWIN $3,316,000.00
- MYGN $832,900,000.00
- Revenue This Year
- SWIN $29.79
- MYGN $0.17
- Revenue Next Year
- SWIN $54.60
- MYGN $6.19
- P/E Ratio
- SWIN N/A
- MYGN N/A
- Revenue Growth
- SWIN N/A
- MYGN 3.83
- 52 Week Low
- SWIN $1.16
- MYGN $3.76
- 52 Week High
- SWIN $5.09
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- SWIN 38.47
- MYGN 69.11
- Support Level
- SWIN $2.45
- MYGN $7.13
- Resistance Level
- SWIN $2.90
- MYGN $7.80
- Average True Range (ATR)
- SWIN 0.46
- MYGN 0.44
- MACD
- SWIN -0.04
- MYGN 0.05
- Stochastic Oscillator
- SWIN 11.29
- MYGN 92.45
About SWIN Solowin Holdings
Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Corporate Finance Services, Wealth Management Services, Asset Management Services and Virtual Assets. It derives maximum revenue from Wealth Management Services.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.